Search

On June 24, 2022, the U.S. Supreme Court ruling in Dobbs v Jackson Women's Health overturned Roe v Wade , and authority to regulate abortion was returned to individual states. It is critically important for all physicians to understand the implications that this ruling may have on reproductive autonomy with regard to abortion care and in vitro fertilization (IVF). Although the intended consequence of abortion bans is to prohibit legal abortion, one unintended consequence may be undue restriction of in vitro fertilization. We summarize the potential of abortion bans, particularly those with personhood clauses, to affect IVF practice. We detail the implications of these bans on embryo cryopreservation, preimplantation genetic testing, single embryo transfer, and access to infertility treatments. In the United States in 2019, nearly 84,000 children were born as a result of IVF (2.2% of all births), and nearly 250,000 IVF cycles were performed. These bans will have a profound effect beyond abortion, and these implications are not widely understood in the medical community., Competing Interests: Financial Disclosure The authors did not report any potential conflicts of interest., (Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)

Objective: To describe the relationship between a short interpregnancy interval and adverse pregnancy outcomes in the population undergoing assisted reproductive technology., Methods: This is a retrospective analysis using data from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System. The cohort includes patients with a history of live birth from assisted reproductive technology who returned for a fresh, autologous in vitro fertilization (IVF) cycle from 2004 to 2013. Interpregnancy interval was defined as the interval from live birth to cycle start. Logistic regression models of preterm delivery (less than 37 weeks of gestation) and low birth weight (less than 2,500 g) on interpregnancy interval were fit with adjustment for age, body mass index, and history of preterm delivery. Predicted probabilities were generated from the logistic model., Results: Of 51,997 fresh IVF cycles after an index live birth, 17,536 resulted in a repeat live birth with 11,271 singleton live births from autologous IVF. An interpregnancy interval of less than 18 months occurred in 40.9% of cycles. Compared with a reference interpregnancy interval of 12 to less than 18 months, the adjusted odds ratio for singleton preterm delivery was 1.66 (95% CI 1.05-2.65) for an interpregnancy interval less than 6 months and 1.34 (95% CI 1.06-1.69) for 6 to less than 12 months. An interpregnancy interval 6 to less than 12 months was associated with a 3.0% increase in preterm delivery (13.6±1.1% vs 10.6±0.7%, P=.030) and a 2.7% increase in low birth weight (8.0±0.9% vs 5.3±0.5%, P=.025) compared with an interpregnancy interval of 12 to less than 18 months., Conclusion: In this nationally representative population, an interval from delivery to treatment start of less than 12 months is associated with increased rates of preterm delivery and low birth weight in singleton live births from assisted reproductive technology. The data support delaying the start of IVF treatment 12 months from a live birth, but do not suggest a benefit from a longer interval as has been recommended for naturally conceiving couples.

Objective: To estimate whether women aged 20-32 years who fulfilled National Institutes of Health criteria for polycystic ovary syndrome (PCOS) would be at higher risk for subsequent development of incident diabetes, dyslipidemia, and hypertension, and to estimate whether normal-weight women with PCOS would have the same degree of cardiovascular risk as overweight women with PCOS., Methods: We estimated the association of PCOS with incident diabetes, dyslipidemia, and hypertension over a period of 18 years among 1,127 white and African-American women in the Coronary Artery Risk Development in Young Adults cohort. We classified women at baseline (ages 20-32 years) based on self-reported symptoms and serum androgen measures using National Institutes of Health PCOS criteria. We estimated the association of PCOS and subsequent cardiovascular risk factors, independent of baseline body mass index (BMI), using multivariable logistic regression. Additionally, among 746 women with a second assessment of PCOS at ages 34-46 years, we estimated the association of persistent PCOS with cardiovascular risk factors., Results: Of 1,127 women, 53 (4.7%) met criteria for PCOS at ages 20-32 years. Polycystic ovary syndrome was associated with a twofold higher odds of incident diabetes (23.1% compared with 13.1%, adjusted odds ratio [AOR] 2.4, confidence interval [CI] 1.2-4.9) and dyslipidemia (41.9% compared with 27.7%, AOR 1.9, CI 1.0-3.6) over the course of 18 years; the association with incident hypertension was not significant (26.9% compared with 26.3%, AOR 1.7, CI 0.8-3.3). Normal-weight women with PCOS (n=31) had a threefold higher odds of incident diabetes compared with normal-weight women without PCOS (AOR 3.1, CI 1.2-8.0). Compared with those without PCOS, women with persistent PCOS (n=11) had the highest odds of diabetes (AOR 7.2, CI 1.1-46.5)., Conclusion: Polycystic ovary syndrome is associated with subsequent incident diabetes and dyslipidemia, independent of BMI. Diabetes risk may be greatest for women with persistent PCOS symptoms., Level of Evidence: II.

Sixty postmenopausal women were enrolled in a 2-year randomized unmasked trial to determine the long-term safety of estradiol (E2) administration by a transdermal therapeutic system. Group I subjects received 0.1 mg of transdermal E2 for 24.5 days of each 28-day cycle for 96 weeks. Group II subjects received the same dosage of transdermal E2 plus 10 mg of medroxyprogesterone acetate, given orally from days 13-25 of each cycle. Vaginal bleeding patterns and endometrial histology were characterized. The subjects recorded bleeding patterns daily. Endometrial biopsies were performed during scheduled follow-up visits at 48 and 96 weeks or as needed to evaluate abnormal bleeding. Data were analyzed by intention to treat. Ten and four subjects dropped out of the study from groups I and II, respectively. A total of 575 and 627 treatment cycles were observed in the same respective groups. Vaginal bleeding was observed in 980 cycles: 381 of 575 cycles in group I (66.3%) and 599 of 627 cycles in group II (95.5%). Bleeding onset, duration, and quantity were similar for both groups. The incidence of hyperplasia was 42 and 4% for groups I and II, respectively, over the 96-week study period. All cases of hyperplasia in group I were treated with sequential medroxyprogesterone acetate for 12 weeks, followed by rebiopsy. In ten of 11 cases, the progestin therapy converted the hyperplasia to a normal endometrium. In one case, the endometrium became hyperplastic again at 96 weeks, but reverted to normal with 12 weeks of medroxyprogesterone acetate.(ABSTRACT TRUNCATED AT 250 WORDS)

Highly potent agonists of gonadotropin-releasing hormone (GnRH) have been shown to reduce pelvic pain due to endometriosis and the size and number of implants seen at laparoscopy. The accompanying symptoms and problems associated with the hypoestrogenism induced by the agonist have reduced its acceptability and raised questions about its safety. In an attempt to optimize this form of therapy, we treated eight women with endometriosis with daily subcutaneous injections of a potent agonist of GnRH plus a daily oral dose of 20-30 mg of medroxyprogesterone acetate for 24 weeks. Ovarian estrogen secretion was reduced to levels seen in castrated women throughout the course of treatment. Markers of hypoestrogenism, such as hot flashes and loss of calcium from bone, were diminished with this regimen compared with previous findings with GnRH agonist alone. Blinded evaluation of laparoscopic photographs failed to reveal improvement or suppression of active endometriosis. The results of this pilot study indicate that the addition of medroxyprogesterone acetate decreases the hypoestrogenic effects of GnRH agonist alone but fails to affect pain or endometriotic implants.